Product logins

Find logins to all Clarivate products below.


Market Event Summary Hub

Market Event Summaries provide data‑driven insights into key trends shaping the life sciences and healthcare markets. Developed using insights from DRG Commercial Solutions, these summaries support market access, commercialization, and disease intelligence decision‑making across policy, payer, epidemiology, and market assessment topics.

May 2026
Orforglipron expanding the obesity GLP1 market
Market access February 2026
HAE innovation and coverage shifts
Market access February 2026
Medicaid’s Cell & Gene Therapy
Market access December 2025
Insulin Biosimilar Trends
Strategic planning & market assessment November 2025
First SMM FDA approval – November 2025
Strategic planning & market assessment November 2025
Mazdutide tops semaglutide in head-to-head study
Strategic planning & market assessment November 2025
GSK’s Blenrep returns to the U.S. market with significant caveats
Strategic planning & market assessment October 2025
Pavblu’s first year in review
Strategic planning & market assessment October 2025
Clarivate’s top takeaways from ESMO 2025
Strategic planning & market assessment October 2025
First Xolair biosimilar enters Europe
Market access October 2025
GLP-1 2025 Trends
Market access October 2025
Generics Drug Uptake Trends
Strategic planning & market assessment September 2025
Icotrokinra outperforms oral competitor deucravacitinib in a head-to-head plaque psoriasis trial
Strategic planning & market assessment September 2025
Keytruda Qlex FDA approval
Strategic planning & market assessment September 2025
Clarivate’s top takeaways from the 2025 World Conference on Lung Cancer
Strategic planning & market assessment September 2025
Inlexzo a potentially paradigm-shifting therapy in non-muscle-invasive bladder cancer
Strategic planning & market assessment August 2025
Wegovy breaks new ground, FDA Greenlights MASH indication
Strategic planning & market assessment August 2025
Venetoclax in MDS from breakthrough to bottleneck
Strategic planning & market assessment July 2025
NMPA approves mazdutide for weight management
Strategic planning & market assessment July 2025
COMP360 achieves success in the initial phase of a pivotal study for treatment-resistant depression
Market access July 2025
Navigating the Biosimilars Battleground – Humira vs. Biosimilars
Strategic planning & market assessment June 2025
FDA approves Keytruda for perioperative use in PD-L1+ locally advanced SCCHN
Strategic planning & market assessment June 2025
Clarivate’s top takeaways from ASCO 2025
Strategic planning & market assessment June 2025
First denosumab biosimilar debuts in the United States
Strategic planning & market assessment May 2025
CID Breast Cancer
Strategic planning & market assessment May 2025
FDA approves AbbVie’s Emrelis
Strategic planning & market assessment May 2025
Keytruda plus chemotherapy extends overall survival in recurrent ovarian cancer
Strategic planning & market assessment May 2025
FDA approves Dupixent for chronic spontaneous urticaria
Strategic planning & market assessment May 2025
Biosimilar clinical development gains momentum
Strategic planning & market assessment April 2025
Pluvicto in pre-chemo mCRPC
Strategic planning & market assessment April 2025
ACC 2025 Clarivates take on the five key presentations
Strategic planning & market assessment April 2025
Corcept’s relacorilant improves PFS and OS in platinum-resistant ovarian cancer
Strategic planning & market assessment April 2025
FDA ALIGNs with Vanrafia, grants accelerated approval for IgA nephropathy
Strategic planning & market assessment March 2025
Formycon seeks FDA approval for pembrolizumab biosimilar without Phase 3 trial
Market access March 2025
Private equity firm scoops up Walgreens 2025
Strategic planning & market assessment March 2025
KOR antagonists struggle to address anhedonia in late phase studies in MDD
Strategic planning & market assessment February 2025
Enhertu metastatic breast cancer
Strategic planning & market assessment December 2024
Zepbound tops Wegovy in a head-to-head obesity trial
Strategic planning & market assessment December 2024
NSCLC: 2024 highlights and key market – impacting events to watch in 2025
Strategic planning & market assessment December 2024
Rethinking Disease Modification in Parkinson’s Disease
November 2024
New data and developments set to shift dynamics in the anti ABMAb space
Strategic planning & market assessment November 2024
Biosimilars interchangeability evolving market and treatment landscape
Strategic planning & market assessment November 2024
Pavblu launches in the U.S. market
Strategic planning & market assessment October 2024
PBMs to remove Humira from formularies
Strategic planning & market assessment October 2024
Oxbryta’s global exit, Pfizer withdraws SCD drug amid safety concerns
October 2024
Clarivate Market Event Summary – With FDA approval, Cobenfy is set to make inroads into the schizophrenia treatment pathway
Strategic planning & market assessment September 2024
Weekly insulins treatment landscape and market outlook
Strategic planning & market assessment September 2024
First Stelara biosimilars debut in Europe and Japan, with a U.S. launch on the horizon
Strategic planning & market assessment September 2024
Mosaic Health Elevance Health’s bold move to transform primary care delivery
September 2024
Clarivate Market Trend Summary – FDA approves Syndax Incyte’s Niktimvo a first in class anti CSF 1R antibody for chronic graft versus host disease
Strategic planning & market assessment September 2024
FDA approves Roche’s Tecentriq Hybreza, the first subcutaneous anti-PD-(L)1 cancer therapy
Strategic planning & market assessment September 2024
Tolebrutinib data refine the niche for BTK inhibitors in MS
Strategic planning & market assessment August 2024
Novartis’s Fabhalta: a first-in-class complement inhibitor and the third therapy in a wave of IgAN therapies
Strategic planning & market assessment August 2024
ODAC vote on perioperative NSCLC trials
Market access July 2024
BCBSM to end coverage for GLP-1 weight loss drugs
Market access July 2024
Walgreens lowers bets on VillageMD
Strategic planning & market assessment July 2024
Clarivate Market Event Summary – Myasthenia Gravis
Strategic planning & market assessment July 2024
Obesity
Strategic planning & market assessment June 2024
MDMA unlikely to receive FDA approval for PTSD in 2024
Strategic planning & market assessment June 2024
Delay in the launch of Eylea biosimilars
Strategic planning & market assessment May 2024
FDA Approves Amgens Imdelltra a Landscape-Changing First-in-Class DLL-3 Targeted BiTE Therapy
Market access May 2024
2024 Walmart Health
Strategic planning & market assessment May 2024
FDA approves Roche’s Alecensa for resectable ALK-positive NSCLC
Strategic planning & market assessment May 2024
Rising tides: the surge and thirst for the GLP-1s
Strategic planning & market assessment May 2024
Ajovy’s Success in Migraine Repeated in the Chinese Study
May 2024
Clarivate Market Event Summary – Ajovy’s Success in Migraine Repeated in the Chinese Study
May 2024
Clarivate Market Event Summary – NSCLC. 2024. Alecensa approved based on ALINA
Strategic planning & market assessment April 2024
Regeneron’s Bispecific Antibody Odronextamab Falls Short on FDA Regulatory Requirements
Strategic planning & market assessment April 2024
Akebia finally scores FDA approval for renal anemia drug vadadustat
Strategic planning & market assessment March 2024
Revolutionizing treatment Opsynvi and Winrevair shake up the PAH market
Strategic planning & market assessment March 2024
Rezdiffra the first drug approved for NASH
Strategic planning & market assessment March 2024
Pimavanserin fails in schizophrenia
Strategic planning & market assessment March 2024
FDA approves Iovance’s Amtagvi a first-in-class autologous cell therapy for melanoma
Market access February 2024
HCSC Makes MA Moves 2024
Strategic planning & market assessment February 2024
Myasthenia Gravis February 2024
Market access February 2024
Cost-plus drug pricing: the latest project among top PBMs and payers